Table 1

Clinical and laboratory characteristics of patients with GPA and healthy controls

Patients with GPA in remission

Patients with active GPA

Healthy controls


Number

12

14

20

Age in years, mean (range)

58 (38-83)

55 (27-77)

51 (21-78)

Sex, male/female

10/2

10/4

11/9

BVAS V3.0, mean (range)

0

10 (4-21)

CRP in mg/L, mean (range)

8 (1-17)

33 (1-86)

PR3-ANCA, positive/negative

9/3

14/0

Methotrexate, number

9

5

Azathioprine, number

1

0

Leflunomide, number

2

0

Cyclophosphamide, number

0

5

Prednisolone, number

12

10

Prednisolone dosage in mg

6.1 ± 0.8

11.9 ± 1.9a

No treatment

0

4


Remission was defined as BVAS V3.0 (Birmingham Vasculitis Activity Index version 3.0) of 0. Disease activity in patients either with first manifestation or relapsing was defined as BVAS V3.0 of at least 1 (15). Prednisolone dosage is expressed as mean ± standard error of the mean. aP < 0.05 by Mann-Whitney U test. CRP, C-reactive protein; GPA, granulomatosis with polyangiitis; PR3-ANCA, anti-neutrophil cytoplasmic autoantibodies targeting proteinase 3.

Fagin et al. Arthritis Research & Therapy 2012 14:R73   doi:10.1186/ar3794

Open Data